(LIVN) LivaNova PLC Business Model Canvas Research

Clinical trial sites and investigators are core partners for LivaNova PLC because they run VITARIA System and other studies, generate the clinical evidence needed for regulatory and reimbursement filings, and drive execution in neuromodulation and cardiovascular trials. In these programs, investigator-led sites are the main source of endpoint data and real-world safety follow-up.

• Support VITARIA and pipeline studies
• Build FDA and payer evidence
• Enable investigator-led trial execution

LivaNova PLC depends on uninterrupted supply of components, raw materials, and device parts, because any delay can hit both implantable systems and disposable cardiopulmonary products. Manufacturing partners also help LivaNova PLC meet global quality rules and keep production stable across sites.

• Protects supply continuity
• Supports global quality control
• Covers implantable and disposable lines

Commercial teams sell to hospitals, physicians, and distributors, while field specialists help drive adoption in operating rooms and clinical centers. This spans all three operating segments; LivaNova PLC reported about $1.2 billion in net sales in FY2024, so global sales and commercial support remains a core revenue engine.

• Sell to hospitals, physicians, distributors
• Support OR and clinical adoption
• Span all three operating segments

LivaNova PLC’s post-market service and training keep surgeons, perfusionists, and care teams using implantable and life-support devices correctly, which supports procedural success, uptime, and clinical confidence. Ongoing support matters most after implant because even small use errors can affect outcomes and the value of the installed base.

• Train users for safe device handling
• Support procedure success and confidence
• Maintain installed base performance
• Reduce risk in life-support use

Clinical data is a key resource for LivaNova PLC: it supports current products, backs new indications, and helps with FDA, CE Mark, and payer credibility. The VITARIA System program extends that pipeline, while LivaNova PLC’s latest filings show annual net sales above $1 billion, giving it scale to fund further studies.

• Supports current products
• VITARIA adds future indications
• Strengthens regulatory credibility

LivaNova PLC uses a direct sales force plus independent distributors to reach hospitals and physicians across multiple countries, which is practical for a medtech business with different buying paths and local rules. This model supports market access in both large health systems and smaller accounts, while keeping commercial coverage close to the customer.

• Direct teams cover key accounts
• Distributors extend local reach
• Fits hospital and physician needs

The VITARIA System extends LivaNova PLC’s vagus nerve stimulation into heart failure, opening a new route beyond epilepsy and depression. That matters in a market where heart failure affects about 64 million people worldwide, so even modest clinical success could broaden LivaNova PLC’s cardiovascular neuromodulation reach.

• Heart failure is a large unmet-need market.
• VITARIA expands VNS beyond current uses.
• Supports future cardiovascular growth.

LivaNova PLC’s global clinical and procedural support helps physicians and hospitals adopt therapies faster, build confidence, and use devices more consistently across surgical, neurology, and critical-care workflows. The company’s reach spans more than 100 countries, so this support scales from first case to routine use.

• Training lifts adoption and confidence.
• Service supports safer, steadier use.
• Cross-workflow help boosts utilization.

That matters because every added procedure-trained team can reduce setup friction and improve repeat use, which supports revenue across implant and capital-heavy care settings.

LivaNova PLC uses independent distributors to handle local customer service in many markets, which helps with language, logistics, and local norms. For a Company that reported 2025 revenue of about $1.2 billion, this model extends reach without building full direct support in every country.

• Local contact, faster issue handling
• Better language and market fit
• Lower direct coverage cost

LivaNova PLC’s technical support and post-market follow-up must be fast because its devices sit in implantable and life-support care paths, where users need immediate help and clinicians need monitoring. The company reported 2025 net sales of about $1.2 billion, so even small service failures can affect a large installed base.

Follow-up tracks device performance and clinical outcomes after implant, which helps reduce risk and guide therapy changes. For this customer relationship, support speed and field data matter as much as the device itself.

• Fast help protects critical care use.
• Follow-up improves outcomes and device performance.

LivaNova PLC uses clinical education events to turn product claims into peer-validated practice, with training sessions and scientific meetings explaining clinical value to specialists. In 2024, the Company generated about $1.2 billion in net sales, and these forums help convert that scale into adoption by building trust, shortening the learning curve, and reinforcing clinician-to-clinician credibility.

• Training boosts specialist awareness
• Scientific meetings support adoption
• Peer voices strengthen credibility

LivaNova PLC uses a mix of field teams and digital channels to share product information, deliver training, and keep follow-up tight across markets. This matters because the Company reported 2025 net sales of $1.2 billion, so steady outreach helps support demand and service across its neuromodulation and cardiovascular base.

• Field visits support complex clinical training
• Digital touchpoints speed product updates
• Follow-up keeps global accounts engaged

Hospitals are LivaNova PLC’s core buyers for capital equipment, disposables, and therapy systems, so they shape access across cardiac and neurotherapy care. Procurement is usually institution-led, with decisions driven by clinical teams, value analysis groups, and budget cycles, which can slow sales but support larger, repeat system placements.

• Buy capital, disposables, and therapy systems
• Institution-led procurement drives access
• Central to repeat product use

Healthcare providers are LivaNova PLC’s core buyer group: physicians and clinical teams in surgery, neurology, and critical care use its devices in procedure-based care, so clinical preference can swing revenue fast. LivaNova reported about $1.2 billion in annual sales in 2024, and each product choice is tied to outcomes, training, and surgeon trust.

• Physicians drive product choice.
• Procedure use links to sales.
• Trust and outcomes matter most.

LivaNova PLC’s sales, marketing, and distributor support cost base is driven by field teams, clinical education, and channel management, plus the coordination needed to keep distributor programs aligned across markets. Because the Company sells through a global footprint, these costs track market reach and product adoption more than factory volume.

• Field teams drive specialist sales
• Education supports physician adoption
• Distributor programs need close coordination
• Global reach lifts fixed commercial costs

LivaNova PLC’s administrative and corporate overhead is the cost of being a London-headquartered, regulated multinational: finance, legal, compliance, board governance, and SEC/UK reporting. In FY2025, these fixed corporate layers supported a global medtech group with about $1.2 billion in revenue, so overhead stays material even when sales shift by region.

• Finance, legal, compliance, governance
• Supports UK and U.S. reporting
• Fixed cost for multinational control

LivaNova PLC’s recurring revenue comes from disposable and replacement parts used in procedures, which can turn one surgery into repeat orders over time. In FY2024, Company Name reported revenue of about $1.2 billion, and its procedure-led device mix supports a more recurring commercial profile through ongoing consumable use.

• Disposable parts drive repeat orders.
• Replacement demand supports steady sales.
• Procedure use creates ongoing volume.

LivaNova PLC uses international distributor sales to widen geographic reach and add income from healthcare markets it does not serve directly. This channel supports direct sales by giving the Company more local access, faster market entry, and a broader revenue mix.

• Broader geographic revenue base
• Access to more healthcare markets
• Supports direct sales coverage